FDA OKs First Gene Therapy for Spinal Muscular Atrophy

A single, one-time infusion of onasemnogene abeparvovec-xioi (Zolgensma) can minimize the progression of SMA and improve survival in children younger than age 2 years — and will cost over $2 million.
FDA Approvals

Source link

Related posts

The biology of cutaneous neurofibromas: Consensus recommendations for setting research priorities


ZTlido Patch for Post-Shingles Pain Launching Soon


Author response: Outcome after seizure recurrence on antiepileptic drug withdrawal following temporal lobectomy


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy